Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa

马拉维和南非的艾滋病毒癌症筛查和预后创新，包括卡波西肉瘤、宫颈癌和淋巴瘤

• 批准号: 10084552
• 负责人: Carla J Chibwesha
• 金额: $ 118.05万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-13 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10084552
• 关键词: AIDS Malignancy Consortium; AIDS clinical trial group; AIDS related cancer; AIDS-Related Lymphoma; AIDS/HIV problem; Achievement; Acquired Immunodeficiency Syndrome; Address; Africa; Africa South of the Sahara; Basic Science; Biological Markers; Cancer Burden; Cancer Control; Cancer Prognosis; Caring; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communicable Diseases; Communities; Comprehensive Cancer Center; Crystallization; Data; Ensure; Epidemic; Flowers; Goals; HIV; Health; Hospitals; Individual; Infrastructure; Institutes; Institution; International; Kaposi Sarcoma; Knowledge; Leadership; Lymphoma; Malawi; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Medicine; Methods; Molecular; North Carolina; Patients; Persons; Policies; Population Sciences; Positioning Attribute; Principal Investigator; Recurrence; Research; Research Infrastructure; Research Personnel; Research Priority; Research Project Grants; Science; Site; South Africa; South African; Survival Rate; Training; Training Support; Training and Infrastructure; Translational Research; Trust; UNC Lineberger Comprehensive Cancer Center; United States National Institutes of Health; Universities; anticancer research; antiretroviral therapy; career; clinical research site; college; combat; comorbidity; data sharing; epidemiology study; global health; high risk; improved; innovation; insight; low and middle-income countries; next generation; oncology program; outcome forecast; programs; response; screening; success; translational impact; tumor

ABSTRACT: OVERALL COMPONENT: Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa In response to RFA-CA-20-001, this application proposes to establish the UNC-Malawi-South Africa Cancer Consortium (UMSACC), to develop capacity and conduct high-impact research focused on HIV-associated cancers. The consortium builds on longstanding collaborations between the University of North Carolina at Chapel Hill, Lighthouse Trust in Malawi, Malawi Ministry of Health, Malawi College of Medicine, the University of the Witwatersrand, South Africa, and Stellenbosch University, South Africa. These partnerships have been made possible by leadership and participation in NIH networks conducting basic, clinical and epidemiologic research in the region. These existing relationships and robust infrastructure can now be leveraged for HIV- associated malignancies, which are overwhelming contributors to cancer burden in Malawi and South Africa even after widespread antiretroviral therapy usage. UMSACC is focused on the three most common HIV- associated cancers, Kaposi sarcoma (KS), cervical cancer, and lymphoma, and addresses the NIH HIV/AIDS research priorities by focusing on HIV-associated comorbidities which includes these AIDS-defining cancers. UMSACC proposes innovations for screening and prognosis of these cancers in persons living with HIV (PLWH) with the overall goal being to improve the health of PLWH. Our consortium will be led by principal investigators with highly complementary expertise using a team science approach. To support consortium objectives, a diverse team of investigators has been assembled spanning the clinical, population, and basic sciences, and includes Malawian, South African, and US scientific leaders. Moreover, a high priority is the training and support of junior investigators in the U.S. and Africa. The consortium will enhance existing administrative, operational, and research relationships between all partnering institutions and investigators. The External Advisory Board and Scientific Advisors will ensure that the consortium remains highly responsive to community needs in Malawi and South Africa, while also addressing urgent research questions facing the international HIV-associated cancer community. A focus of this consortium is to develop Malawi and South Africa to become international leaders in HIV- associated cancer research. Building on prior successes and partnerships outlined in this application, UMSACC is extremely well-positioned to catalyze a broad, coordinated, cancer control effort in Malawi and South Africa, and to advance the overall NCI scientific agenda for sub-Saharan Africa to reduce HIV- associated cancer burden in low- and middle-income countries.

摘要：总体组成部分：HIV+癌症筛查和预后的创新 包括马拉维和南非的卡波西肉瘤、宫颈癌和淋巴瘤 为了响应 RFA-CA-20-001，本申请提议建立 UNC-马拉维-南非癌症中心 联盟（UMSACC），旨在发展能力并开展重点关注艾滋病毒相关的高影响力研究 癌症。该联盟建立在北卡罗来纳大学之间的长期合作基础上 教堂山、马拉维灯塔信托基金、马拉维卫生部、马拉维医学院、大学 南非威特沃特斯兰德大学和南非斯泰伦博斯大学。这些伙伴关系已 通过领导和参与 NIH 网络进行基础、临床和流行病学研究，使之成为可能 该地区的研究。现在可以利用这些现有的关系和强大的基础设施来应对艾滋病毒 相关恶性肿瘤是马拉维和南非癌症负担的主要原因 即使在广泛使用抗逆转录病毒疗法之后。 UMSACC 专注于三种最常见的 HIV- 相关癌症、卡波西肉瘤 (KS)、宫颈癌和淋巴瘤，并解决了 NIH HIV/AIDS 问题 通过关注与艾滋病毒相关的合并症（包括这些艾滋病定义的癌症）来确定研究重点。 UMSACC 提出对艾滋病毒感染者的这些癌症进行筛查和预后的创新 （PLWH），总体目标是改善 PLWH 的健康。 我们的联盟将由具有高度互补专业知识的主要研究人员领导，利用团队科学 方法。为了支持联盟的目标，已经组建了一个横跨各个领域的多元化研究团队 临床、人口和基础科学领域，包括马拉维、南非和美国的科学领袖。 此外，当务之急是对美国和非洲初级研究人员的培训和支持。这 联盟将加强所有合作伙伴之间现有的管理、运营和研究关系 机构和调查人员。外部顾问委员会和科学顾问将确保 财团仍然高度响应马拉维和南非的社区需求，同时也解决 国际艾滋病相关癌症界面临的紧迫研究问题。 该联盟的重点是使马拉维和南非成为艾滋病毒领域的国际领导者。 相关的癌症研究。基于本申请中概述的先前成功和合作伙伴关系， UMSACC 处于非常有利的位置，可以促进马拉维和其他国家开展广泛、协调的癌症控制工作 南非，并推进撒哈拉以南非洲国家癌症研究所的总体科学议程，以减少艾滋病毒 低收入和中等收入国家的相关癌症负担。